Key result
Statin treatment in the acute phase did not significantly alter the risk of post-stroke pneumonia among patients with acute ischemic stroke (OR 1.57, 95% CI 0.77-3.18).
Why the study?
The effects of statins on post-stroke pneumonia were uncertain, prompting an investigation into the impact of acute-phase statin treatment on the risk and severity of post-stroke pneumonia.
Does statin treatment in the acute phase reduce the risk of post-stroke pneumonia in patients with acute ischemic stroke?
Cohort (n=1,258)
No
Does statin treatment in the acute phase reduce the risk of post-stroke pneumonia in patients with acute ischemic stroke?
Odds Ratio: 1.57 (95% CI 0.77–3.18)
Absolute Event Rate: 35.1% vs 27.9%
p-value: p=0.213
Statin treatment in the acute phase of ischemic stroke does not appear to reduce the risk or severity of post-stroke pneumonia.
No takes yet. Share an insight, caveat, or question.
Acute statins should not yet inform pneumonia prevention in ischemic stroke; leaves open causal effects pending randomized data.
Li et al. (2021) conducted a cohort in Acute ischemic stroke (n=1,258). Statin treatment in the acute phase vs. No statin treatment was evaluated on Risk of post-stroke pneumonia during hospital stay (OR 1.57, 95% CI 0.77-3.18, p=0.213). Statin treatment in the acute phase did not significantly alter the risk of post-stroke pneumonia among patients with acute ischemic stroke (OR 1.57, 95% CI 0.77-3.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: